HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.

AbstractSTUDY OBJECTIVE:
To determine whether changes in serum glucose, serum potassium, and plasma insulin levels are correlated in a cohort of hypertensive patients.
DESIGN:
Prespecified subgroup analysis of results from a prospective, multicenter, randomized, open-label, parallel-group study. Setting. Primary care clinics at three tertiary care medical centers.
PATIENTS:
Community-based ambulatory population of 202 patients (age range 17-65 yrs) with a new diagnosis of hypertension, untreated hypertension, or known hypertension, who were previously treated with fewer than three antihypertensive drugs and had no evidence of cardiovascular disease or diabetes mellitus. Intervention. Monotherapy with oral hydrochlorothiazide 12.5 or 25 mg/day for 9 weeks.
MEASUREMENTS AND MAIN RESULTS:
Fasting serum glucose, serum potassium, and plasma insulin levels were obtained at baseline (before hydrochlorothiazide therapy was started) and after 9 weeks of therapy. Significant elevations were noted in fasting serum glucose (mean +/- SD 3.42 +/- 10.38 mg/dl, p<0.0001) and plasma insulin (2.35 +/- 9.47 microU/ml, p<0.0001) levels, and a significant reduction in serum potassium level (0.30 +/- 0.44 mEq/L, p<0.0001) was noted. No significant correlation was observed between changes in fasting serum glucose and potassium levels (r = 0.022, 95% confidence interval (CI) -0.120-0.164, p=0.757) or between changes in serum potassium and plasma insulin levels (r = -0.112, 95% CI -0.256-0.037, p=0.140). Changes in serum glucose levels did not differ significantly between patients maintaining serum potassium levels of 4.0 mEq/L or greater and those with levels below 4.0 mEq/L.
CONCLUSION:
Changes in serum potassium and serum glucose levels were not correlated in individuals receiving hydrochlorothiazide monotherapy; thus maintenance of normal potassium levels may not attenuate the risk of thiazide diuretic-induced hyperglycemia.
AuthorsSteven M Smith, Shawn D Anderson, Sheron Wen, Yan Gong, Stephen T Turner, Rhonda M Cooper-Dehoff, Gary L Schwartz, Kent Bailey, Arlene Chapman, Karen L Hall, Hua Feng, Eric Boerwinkle, Julie A Johnson, John G Gums
JournalPharmacotherapy (Pharmacotherapy) Vol. 29 Issue 10 Pg. 1157-65 (Oct 2009) ISSN: 1875-9114 [Electronic] United States
PMID19792989 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antihypertensive Agents
  • Blood Glucose
  • Insulin
  • Hydrochlorothiazide
  • Potassium
Topics
  • Adolescent
  • Adult
  • Aged
  • Antihypertensive Agents (administration & dosage, adverse effects, therapeutic use)
  • Blood Glucose (drug effects)
  • Female
  • Humans
  • Hydrochlorothiazide (administration & dosage, adverse effects, therapeutic use)
  • Hyperglycemia (chemically induced)
  • Hypertension (drug therapy)
  • Hypokalemia (chemically induced)
  • Insulin (blood)
  • Male
  • Middle Aged
  • Potassium (blood)
  • Randomized Controlled Trials as Topic
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: